STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Sientra, Inc. (Nasdaq: SIEN) (“Sientra” or the “Company”) securities during the period between March 18, 2015 and September 24, 2015, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until November 24, 2015 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Sientra securities purchased on or after March 18, 2015 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at email@example.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company securities during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Sientra’s exclusive reliance on Silimed’s Brazilian manufacturing facilities carried significant quality control risks, that the manufacturing processes at the Silimed Rio de Janeiro manufacturing plant were contaminated and that the Company’s statements regarding quality control and other financial statements were materially false and misleading.
According to the complaint, following the Company’s September 24, 2015 announcement that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency suspended sales of Silimed products after an audit of Silimed’s manufacturing processes revealed contamination in Silimed’s Rio de Janeiro manufacturing plant, the value of Sientra shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.